![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Metrochem API Private Limited](https://www.pharmacompass.com/image/flap/metrochem-desktop-header-w24-1gif-62145.gif)
![Metrochem API Private Limited](https://www.pharmacompass.com/image/flap/metrochem-mobgif-80388.gif)
Active Filter(s):
Details:
The collaboration expands FibroGen’s clinical pipeline with potential first-in-class product candidate, FOR46, a potential first-in-class Phase 1 ADC targeting a novel epitope on CD46, being developed for the treatment of metastatic castration-resistant prostate cancer.
Lead Product(s): FOR46
Therapeutic Area: Oncology Product Name: FOR46
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: FibroGen
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 08, 2023